230 related articles for article (PubMed ID: 24552977)
1. Effects of low-dose paroxetine 7.5 mg on weight and sexual function during treatment of vasomotor symptoms associated with menopause.
Portman DJ; Kaunitz AM; Kazempour K; Mekonnen H; Bhaskar S; Lippman J
Menopause; 2014 Oct; 21(10):1082-90. PubMed ID: 24552977
[TBL] [Abstract][Full Text] [Related]
2. Low-dose paroxetine 7.5 mg for menopausal vasomotor symptoms: two randomized controlled trials.
Simon JA; Portman DJ; Kaunitz AM; Mekonnen H; Kazempour K; Bhaskar S; Lippman J
Menopause; 2013 Oct; 20(10):1027-35. PubMed ID: 24045678
[TBL] [Abstract][Full Text] [Related]
3. Another option for menopausal vasomotor symptoms without negative impact on weight and sexual function.
Bachmann G
Menopause; 2014 Oct; 21(10):1036-7. PubMed ID: 25072955
[No Abstract] [Full Text] [Related]
4. Low-dose paroxetine (7.5 mg) improves sleep in women with vasomotor symptoms associated with menopause.
Pinkerton JV; Joffe H; Kazempour K; Mekonnen H; Bhaskar S; Lippman J
Menopause; 2015 Jan; 22(1):50-8. PubMed ID: 25137243
[TBL] [Abstract][Full Text] [Related]
5. Safety of low-dose paroxetine.
Pines A
Climacteric; 2014 Jun; 17(3):313-4. PubMed ID: 24945035
[No Abstract] [Full Text] [Related]
6. Paroxetine controlled release in the treatment of menopausal hot flashes: a randomized controlled trial.
Stearns V; Beebe KL; Iyengar M; Dube E
JAMA; 2003 Jun; 289(21):2827-34. PubMed ID: 12783913
[TBL] [Abstract][Full Text] [Related]
7. Diary of hot flashes reported upon occurrence: results of a randomized double-blind study of raloxifene, placebo, and paroxetine.
Simon JA; Chandler J; Gottesdiener K; Lazarus N; He W; Rosenberg E; Wagner JA; Denker AE
Menopause; 2014 Sep; 21(9):938-44. PubMed ID: 24569618
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of Low-Dose Paroxetine for the Treatment of Hot Flushes in Surgical and Physiological Postmenopausal Women: Systematic Review and Meta-Analysis of Randomized Trials.
Riemma G; Schiattarella A; La Verde M; Zarobbi G; Garzon S; Cucinella G; Calagna G; Labriola D; De Franciscis P
Medicina (Kaunas); 2019 Aug; 55(9):. PubMed ID: 31480427
[No Abstract] [Full Text] [Related]
9. Role of paroxetine in the management of hot flashes in gynecological cancer survivors: Results of the first randomized single-center controlled trial.
Capriglione S; Plotti F; Montera R; Luvero D; Lopez S; Scaletta G; Aloisi A; Serra GB; Angioli R
Gynecol Oncol; 2016 Dec; 143(3):584-588. PubMed ID: 27751589
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness of low doses of paroxetine controlled release in the treatment of major depressive disorder.
Trivedi MH; Pigotti TA; Perera P; Dillingham KE; Carfagno ML; Pitts CD
J Clin Psychiatry; 2004 Oct; 65(10):1356-64. PubMed ID: 15491239
[TBL] [Abstract][Full Text] [Related]
11. Relapse of vasomotor symptoms after discontinuation of the selective serotonin reuptake inhibitor escitalopram: results from the menopause strategies: finding lasting answers for symptoms and health research network.
Joffe H; Guthrie KA; Larson J; Cohen LS; Carpenter JS; Lacroix AZ; Freeman EW
Menopause; 2013 Mar; 20(3):261-8. PubMed ID: 23435022
[TBL] [Abstract][Full Text] [Related]
12. Effect and safety of paroxetine for vasomotor symptoms: systematic review and meta-analysis.
Wei D; Chen Y; Wu C; Wu Q; Yao L; Wang Q; Wang XQ; Yang KH
BJOG; 2016 Oct; 123(11):1735-43. PubMed ID: 27062457
[TBL] [Abstract][Full Text] [Related]
13. A double-blind, randomized, parallel-group, flexible-dose study to evaluate the tolerability, efficacy and effects of treatment discontinuation with escitalopram and paroxetine in patients with major depressive disorder.
Baldwin DS; Cooper JA; Huusom AK; Hindmarch I
Int Clin Psychopharmacol; 2006 May; 21(3):159-69. PubMed ID: 16528138
[TBL] [Abstract][Full Text] [Related]
14. Paroxetine: a first for selective serotonin reuptake inhibitors - a new use: approved for vasomotor symptoms in postmenopausal women.
Weber L; Thacker HL
Womens Health (Lond); 2014 Mar; 10(2):147-54. PubMed ID: 24601805
[TBL] [Abstract][Full Text] [Related]
15. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial.
Detke MJ; Wiltse CG; Mallinckrodt CH; McNamara RK; Demitrack MA; Bitter I
Eur Neuropsychopharmacol; 2004 Dec; 14(6):457-70. PubMed ID: 15589385
[TBL] [Abstract][Full Text] [Related]
16. A pilot trial assessing the efficacy of paroxetine hydrochloride (Paxil) in controlling hot flashes in breast cancer survivors.
Stearns V; Isaacs C; Rowland J; Crawford J; Ellis MJ; Kramer R; Lawrence W; Hanfelt JJ; Hayes DF
Ann Oncol; 2000 Jan; 11(1):17-22. PubMed ID: 10690382
[TBL] [Abstract][Full Text] [Related]
17. Paroxetine is an effective treatment for hot flashes: results from a prospective randomized clinical trial.
Stearns V; Slack R; Greep N; Henry-Tilman R; Osborne M; Bunnell C; Ullmer L; Gallagher A; Cullen J; Gehan E; Hayes DF; Isaacs C
J Clin Oncol; 2005 Oct; 23(28):6919-30. PubMed ID: 16192581
[TBL] [Abstract][Full Text] [Related]
18. Systematic review and network meta-analysis comparing the efficacy of fezolinetant with hormone and nonhormone therapies for treatment of vasomotor symptoms due to menopause.
Morga A; Ajmera M; Gao E; Patterson-Lomba O; Zhao A; Mancuso S; Siddiqui E; Kagan R
Menopause; 2024 Jan; 31(1):68-76. PubMed ID: 38016166
[TBL] [Abstract][Full Text] [Related]
19. Low-dose estradiol and the serotonin-norepinephrine reuptake inhibitor venlafaxine for vasomotor symptoms: a randomized clinical trial.
Joffe H; Guthrie KA; LaCroix AZ; Reed SD; Ensrud KE; Manson JE; Newton KM; Freeman EW; Anderson GL; Larson JC; Hunt J; Shifren J; Rexrode KM; Caan B; Sternfeld B; Carpenter JS; Cohen L
JAMA Intern Med; 2014 Jul; 174(7):1058-66. PubMed ID: 24861828
[TBL] [Abstract][Full Text] [Related]
20. Critical appraisal of paroxetine for the treatment of vasomotor symptoms.
Carroll DG; Lisenby KM; Carter TL
Int J Womens Health; 2015; 7():615-24. PubMed ID: 26124682
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
